Zanubrutinib, an oral Bruton tyrosine kinase inhibitor (BTKi), demonstrates anti-tumor activity in R/R DLBCL, particularly in MCD-like patients harboring MYD88/CD79B co-mutations.11 Zanubrutinib also selectively antagonizes the tonic BCR signaling pathway, thereby abrogating the constitutive NF-κB activation that defines the molecular pathogenesis of the BN2-like DLBCL subtype.12 Therefore, therapeutic integration of zanubrutinib was prioritized for the MCD-like and BN2-like subtypes. This evidence concerns the gene CD79B and diffuse large B-cell lymphoma.